Tyrosine Kinase Inhibitors: all 10,469 studies that test it

Page 57 of 105. Open to participants first (1,907), then studies with results posted, then the rest; newest registration first within each.

• Pembrolizumab and Lenvatinib for Resectable Hepatocellular CarcinomaActive, not recruitingNCT05389527Phase 2
• Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingNCT05388006Phase 2
• Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DMEActive, not recruitingNCT05387837Phase 2
• Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous LeukemiaActive, not recruitingNCT05384587Phase 2
• Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung CancerActive, not recruitingNCT05384015Phase 2
• To Evaluate Drug-drug Interactions Between HEC585 and Pirfenidone or Nintedanib in Healthy VolunteersCompletedNCT05383131Phase 1
• Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)Active, not recruitingNCT05382364Phase 1
• A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung CancerStatus unknownNCT05380024Phase 2
• Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid TumorsActive, not recruitingNCT05379946Phase 1/2
• A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 MutationsSuspendedNCT05378763Phase 3
• Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLCActive, not recruitingNCT05374603Phase 2
• Surufatinib With or Wothout Immunotherapy for Advanced Colorectal Cancer in Later LineStatus unknownNCT05372198Phase 2
• A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene AlterationsStatus unknownNCT05372120Phase 2
• A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With MyelofibrosisActive, not recruitingNCT05371964Phase 1
• A Clinical Trial of Regorafenib in Patients With Pretreated Advanced MelanomaActive, not recruitingNCT05370807Phase 2
• A Mass Balance and Biotransformation Study of [14C]SKLB1028 in Chinese Healthy Male SubjectsCompletedNCT05369858Phase 1
• Fruquintinib DDI Study With P-gp and BCRP SubstratesCompletedNCT05368805Phase 1
• ZN-c3 for the Treatment of Metastatic Triple-Negative Breast Cancer and Advanced Ovarian CancerWithdrawnNCT05368506Early Phase 1
• A Study Comparing Two Different Capsules, APL-101 and PLB-1001 Capsules, in Healthy Chinese and Caucasian ParticipantsStatus unknownNCT05367388Phase 1
• A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHLWithdrawnNCT05365100Phase 1/2
• Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell TransplantsActive, not recruitingNCT05364762Phase 2
• Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung CancerWithdrawnNCT05364645Phase 2
• Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) MutationsActive, not recruitingNCT05364073Phase 1
• Seleno-L Methionine (SLM)-Axitinib-PembrolizumabActive, not recruitingNCT05363631Phase 1/2
• Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate CancerSuspendedNCT05361915Phase 2
• A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions.Status unknownNCT05361564Phase 2
• Baricitinib for Cutaneous DermatomyositisWithdrawnNCT05361109Phase 2
• A Study on the Effect of AB-106 on the Pharmacokinetics of DigoxinCompletedNCT05357911Phase 1
• A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 PKCompletedNCT05357820Phase 1
• Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T StudyWithdrawnNCT05356897Phase 2
• An Open Label Study of the Effects and Safety of Zanubrutinib in NMOSDs Adult PatientsTerminatedNCT05356858Phase 2
• ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic CancerActive, not recruitingNCT05355298Phase 1/2
• Efficacy and Safety of Low-dose Ibrutinib and Itraconazole in Chronic Graft Versus Host DiseaseStatus unknownNCT05348096Phase 2
• Assessing the Safety and Efficacy of PLB1004 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)Status unknownNCT05347628Phase 1
• A Study of Nemtabrutinib (MK-1026) in China Participants With Relapsed or Refractory Hematologic Malignancies (MK-1026-005)Active, not recruitingNCT05347225Phase 1
• Evaluation of Mass Balance and Absolute Bioavailability of GLPG3667CompletedNCT05335447Phase 1
• Tolerability and Safety of Nintedanib in Myositis Associated Interstitial Lung DiseaseTerminatedNCT05335278Not applicable
• GPL in Patients with Relapsed/refractory Diffuse Large B Cell LymphomaActive, not recruitingNCT05335018Phase 2
• Relative Bioavailability of ESK-001 Tablet Versus Liquid in Healthy ParticipantsCompletedNCT05330858Phase 1
• GM-CLAG in Relapsed/Refractory FLT3-mutated AMLWithdrawnNCT05330377Phase 1
• A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid TumorsStatus unknownNCT05329298Phase 1/2
• An Open-label, Phase I/II Study of PLENA Regimen in Patients With Unresectable Pancreatic Cancer or BTCStatus unknownNCT05327582Phase 1/2
• IN10018 Monotherapy or in Combination With Docetaxel in Gastric or GEJ AdenocarcinomaCompletedNCT05327231Phase 1
• Lazertinib in Patients With NSCLC With Asymptomatic or Mild Symptomatic Brain Metastases After Failure of EGFR TKI.Status unknownNCT05326425Phase 2
• A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Non-Radiographic Axial SpondyloarthritisStatus unknownNCT05324631Phase 3
• Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of TucatinibActive, not recruitingNCT05323955Phase 2
• Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLLStatus unknownNCT05322733Phase 2
• Zanubrutinib for HLHCompletedNCT05320575Phase 3
• Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast CancerActive, not recruitingNCT05319873Phase 1/2
• Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)TerminatedNCT05319028Phase 2
• A Clinical Study to Evaluate the Pharmacokinetics and Bioequivalence of HMPL-523 Tablets Produced by Two Different ManufacturersCompletedNCT05318820Early Phase 1
• Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With VenetoclaxTerminatedNCT05317936Phase 1/2
• DDI Study of OrelabrutinibCompletedNCT05316857Phase 1
• Study of Erdafitinib Intravesical Delivery System for Localized Bladder CancerActive, not recruitingNCT05316155Phase 1/2
• Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic EventsCompletedNCT05313620Phase 4
• Durvalumab Plus Lenvatinib as First-line Treatment for Unresectable Hepatocellular CarcinomaStatus unknownNCT05312216Phase 2
• Treatment With Olverembatinib in CML-CP Patients Who Failed to at Least Two Previously Administered Second-generation TKIs.Status unknownNCT05311943Phase 3
• Niraparib Plus Anlotinib for Recurrent Ovarian CancerStatus unknownNCT05311579Phase 2
• Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia PatientsActive, not recruitingNCT05306301Phase 2
• A Study to Assess Relative Bioavailability of Branebrutinib, From a Tablet Formulation to the Capsule Formulation, the Effect of Food on the Bioavailability of Branebrutinib From a Tablet Formulation, and the Safety and Drug Levels of Branebrutinib From a Tablet Formulation in Healthy ParticipantsCompletedNCT05303220Phase 1
• Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCCActive, not recruitingNCT05301842Phase 3
• A Study of LVGN6051 Combined With Anlotinib in Patient With Soft Tissue SarcomaCompletedNCT05301764Phase 1/2
• A Study Evaluating the Efficacy and Safety of Baricitinib in Systemic SclerosisActive, not recruitingNCT05300932Phase 4
• Phase I Study of TSN084 in Patients With Advanced Malignant Tumors.Active, not recruitingNCT05300438Phase 1
• Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor MutationsCompletedNCT05299125Phase 2
• Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC TumorsCompletedNCT05298176Phase 2
• A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung CancerActive, not recruitingNCT05297890Phase 2
• Pembrolizumab and Lenvatinib in Clear Cell Ovarian CancerActive, not recruitingNCT05296512Phase 2
• Role of Tofacitinib in Vitiligo PatientsStatus unknownNCT05293119Early Phase 1
• Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRCStatus unknownNCT05292417Phase 2
• Tisleizumab Combined With Lenvatinib and XELOX Regimen (Oxaliplatin Combined With Capecitabine) in the First-line Treatment of Advanced and Unresectable Biliary Tract TumorsStatus unknownNCT05291052Phase 2
• Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLLStatus unknownNCT05287984Phase 2
• A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard TherapyStatus unknownNCT05287386Phase 2
• A Study Comparing Four Different Rivoceranib Tablets in Healthy ParticipantsCompletedNCT05287360Phase 1
• Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With LetrozoleActive, not recruitingNCT05286437Phase 2
• TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung CancerStatus unknownNCT05284994Phase 1/2
• A Study of Orelabrutinib in Patients With AQP4-IgG Positive Neuromyelitis Optica Spectrum DisorderStatus unknownNCT05284175Not applicable
• Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Mild Hepatic Impairment Compared to Participants With Normal Hepatic FunctionCompletedNCT05283915Phase 1
• Surufatinib Alone or Combined With Anti-PD-1 mAb in the Treatment of Advanced Hepatocellular CarcinomaStatus unknownNCT05282433Phase 2
• Study to Assess the Plasma Concentration of Tolebrutinib Given as a Tablet to Adult Participants With Renal Impairment Compared to Healthy Participants.CompletedNCT05282030Phase 1
• A Study of Zanubrutinib in Patients With ITPCompletedNCT05279872Phase 2
• FMT Combined With Immune Checkpoint Inhibitor and TKI in the Treatment of CRC Patients With Advanced StageStatus unknownNCT05279677Phase 2
• Combination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19Status unknownNCT05279391Not applicable
• Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid TumorStatus unknownNCT05278364Phase 1/2
• Lazertinib for Patients With NSCLC Harboring Uncommon EGFR MutationsStatus unknownNCT05277701Phase 2
• Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma (RANT Study)Status unknownNCT05277675Not applicable
• Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCTStatus unknownNCT05277454Phase 1
• Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell MalignanciesStatus unknownNCT05275504Phase 1
• Imatinib and Toripalimab in Patients With Locally Advanced/Metastatic Melanoma Harbored With CKIT MutStatus unknownNCT05274438Phase 2
• An Exploratory Basket Study of Pyrotinib Maleate Tablets in HER2 Mutated or Amplified of Metastatic Solid TumorsStatus unknownNCT05274191Phase 2
• A Pilot Study to Assess Changes in Tumor Biology Following Second-line Treatment With Pembrolizumab Plus Lenvatinib in Patients With Advanced Pancreatic Ductal AdenocarcinomaCompletedNCT05273554Phase 1
• Drug-drug Interaction Study with GLPG3667 and Itraconazole in Healthy SubjectsCompletedNCT05272683Phase 1
• A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic LeukemiaTerminatedNCT05268003Phase 2
• Multiparametric Assessment of Bone Response in mCRPC Patients Treated With CabozantinibCompletedNCT05265988Phase 2
• A Food Effect Study of KC1036 in Healthy SubjectsCompletedNCT05265338Not applicable
• A Study of KL590586 in Patients With Advanced Solid TumorsActive, not recruitingNCT05265091Phase 1/2
• Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R MutationCompletedNCT05263947Phase 2
• Optimizing Pembrolizumab Therapy With Timing and Intensification With AxitinibWithdrawnNCT05263609Phase 2
• A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC)Status unknownNCT05262413Phase 1/2
• Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis (ALTER-G-001)Status unknownNCT05262335Phase 2

← Tyrosine Kinase Inhibitors overview